Roche

Overview

Swiss multinational pharmaceutical company re-entering the obesity and cardiovascular space with major GLP-1 manufacturing investment including a new North Carolina facility with digital twin and automation capabilities. Roche re-entered the cardiovascular and metabolic disease area including the obesity market through acquisitions and in-licensing, building a GLP-1 portfolio that required a strategic pivot from its previous personalized medicine model of small volumes with good margins to high-volume, high cost-efficiency manufacturing. Roche invested in a new GLP-1 manufacturing plant in North Carolina that includes digital twin and fully automated warehouse capabilities as part of its strategy to become one of the top three leaders in the obesity market. (Segment 1 (00:00-05:00)) Roche and Chugai designed emicizumab with intentionally low micromolar binding affinity to each target arm, a deliberate safety feature that builds in an intrinsic attenuation analogous to the tight regulatory control of native factor VIII, which is inactivated by activated protein C and other mechanisms. Hemlibra is approved for hemophilia A and B with and without inhibitors, given as a flat 150 mg subcutaneous dose weekly; the auto-injector device completes dosing in approximately 20 seconds, representing a transformative convenience improvement over IV infusion. (Emicizumab Mechanism (10:00-15:00))